3400 One First Canadian Place
Toronto, ON M5X 1A4
Canada
https://www.vaxil-bio.com
Sector(s):Â Healthcare
Industry:Â Biotechnology
Full Time Employees:Â
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A., MBA | Chairman & CFO | 60k | N/A | 1973 |
Dr. Yuval Avnir Ph.D. | Head of R&D & CEO | N/A | N/A | N/A |
Dr. Riva Kovjazin M.D. | Sr. Scientist & Member of Scientific Advisory Board | N/A | N/A | N/A |
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.
Vaxil Bio Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.